Novus Medical is the new exclusive distributor for MagVenture TMS. MagVenture is the Danish medical device company behind MagVenture TMS therapy®, a non-invasive brain stimulation technology used in the treatment of major depressive disorder and as an adjunct therapy for obsessive compulsive disorder (OCD).
The change in distribution in Canada was made as of July 1, 2024. MagVenture chose Novus Medical Inc. for their high level of clinical expertise and customer service that Novus is known to provide to it’s clients. “The intention is to maintain or even better get more focus on the MagVenture products and customers in Canada with more professionals than before” said Kim Flemming Anderson, Canadian Sales Manager for MagVenture. “Providing a high level of service is in our DNA”, said Murray Beaton, President of Novus Medical. “Users of this technology need reliable service to keep patients on their treatment schedules”. “MagVenture users will experience a whole new level of service and support, along with regulated health professionals providing the clinical applications and training.”
“I am thrilled and proud to once again, work with the MagVenture team. It is an honor to be able to properly represent and support all our clients all across Canada”, said Debbie Kavanagh, Clinical Specialist for Novus Medical. Major Depressive Disorder (MDD) is a leading cause of disability worldwide and although several treatment options are currently available, not all patients will benefit from them; In fact, approximately 60% do not respond adequately to conventional treatments such as antidepressants and are therefore in dire need of a treatment alternative. TMS is known to produce an antidepressant effect in over 60% of these hard-to-treat patients.
Transcranial Magnetic Stimulation is a technology that applies rapidly changing magnetic fields to stimulate specific areas in the brain. TMS has been available as a tool for non-invasive brain stimulation for more than three decades and is currently used extensively in clinical psychiatry, and for ongoing academic medical and translational neuroscience research. MagVenture TMS Therapy® is licensed by Health Canada as a treatment for major depressive disorder (MDD) and as an adjunct therapy treatment for obsessive-compulsive disorder (OCD). MagVenture TMS Therapy® is an outpatient procedure with a well-tolerated safety profile with no systemic side effects. The most common side effects are headaches and nausea. MagVenture TMS Therapy® has been clinically available in Canada since 2005 and is currently delivered at hospitals and psychiatric practices nationwide.
For more information about purchasing a MagVenture TMS device, please send a message to info@novusmedical.ca. This medical device is available for purchase exclusively by licensed physicians. For service inquiries, please contact support@novusmedical.ca. Novus Medical is a Burlington Ontario, based medical device supplier. www.novusmedical.ca/magventure
